Abstract: The present disclosure provides a three-dimensional NAND memory device, comprising a NAND string including a memory cell to be inhibited to program, a word line driver, and a controller configured to control the word line driver to perform a programming operation on the memory cell controlled by a selected word line of a plurality of word lines including a first unselected word line adjacent to the selected word line, a first plurality of unselected word lines adjacent to the first unselected word line, and a second plurality of unselected word lines adjacent to the first plurality of unselected word lines. The programming operation includes applying a programming voltage signal to the selected word line; applying a first pass voltage to the first plurality of unselected word lines; and applying a second pass voltage to the second plurality of unselected word lines, the first pass voltage is different from the second pass voltage.

Abstract: The present disclosure provides a magnetic dressing and a preparation method and use thereof, belonging to the technical field of pharmaceutical preparations. The magnetic dressing includes a magnetic layer, a drug-loading layer, and a protective layer that are stacked in sequence, where the magnetic layer includes polyvinyl alcohol, gluten, and iron particles. In the present disclosure, a swallowed magnetic dressing is controlled by an external magnetic field, and the magnetic dressing is moved to a pathological position by changing a direction of the external magnetic field; after the external magnetic field is removed, the magnetic dressing changes from a ring to a sheet, thereby completing attachment of an entire lesion surface to complete treatment by autonomous drug release.

Abstract: Disclosed is a process for the preparation of certain intermediates, e.g. process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof, in an enantioenriched form, which intermediate and processes are useful in the preparation of a BTK inhibitor, such as ibrutinib.

Abstract: Disclosed is a process for the preparation of certain intermediates, e.g. a process R for preparing a compound of formula (I) wherein, R1, R2 and X1 are as defined in the description, and which intermediate and processes are useful in the preparation of a BTK inhibitor, such as ibrutinib.

Abstract: Provided are crystalline forms of the compound of formula (I), which is a nucleoside inhibitor of HCV, processes for the preparation thereof, and pharmaceutical compositions comprising these crystalline forms.